Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

464 public trials 49 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT06083753

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Xenosciences Phoenix, Arizona, United States
  • Arizona Neuroscience Research, LLC Phoenix, Arizona, United States
  • Alta Bates Summit Medical Center Berkeley, California, United States
  • Colorado Springs Neurological Associates Colorado Springs, Colorado, United States
View all 21 locations
View Trial Details
Completed

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • The University of South Alabama Mobile, Alabama, United States
  • St. Joseph's Hospital & Medical Center - Barrow Neurological Institute Phoenix, Arizona, United States
  • CommonSpirit Health Research Institute Carmichael, California, United States
View all 47 locations
View Trial Details
Completed

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

NCT04121221

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Mapi Pharma Research site 08 Birmingham, Alabama, United States
  • Mapi Pharma Research site 11 Cullman, Alabama, United States
  • Mapi Pharma Research site 15 Pasadena, California, United States
  • Mapi Pharma Research site 14 Denver, Colorado, United States
View all 112 locations
View Trial Details
Completed

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

NCT03963375

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Washington University School of Medicine St Louis, Missouri, United States
  • Oklahoma Medical Research Foundation Oklahoma City, Oklahoma, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details

Related conditions